MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Biomarkers

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells

Oncotarget 2018 April [Link] Ciaramella V, Della Corte CM, Di Mauro C, Tomassi S, Di Maro S, Troiani T, Martinelli E, Bianco R, Cosconati S, Pierantoni R, Meccariello R, Chianese R, Ciardiello F, Morgillo F Abstract PURPOSE: Kisspeptin signaling, via its receptors GPR54, could be an essential players in the inhibition of mesothelioma progression, invasion […]

Comments Off on Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells

Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial)

BMJ Open Respiratory Research 2018 February 19 [Link] de Fonseka D, Underwood W, Stadon L, Rahman N, Edey A, Rogers C, Maskell NA Abstract INTRODUCTION: Pleural malignancy, particularly malignant pleural mesothelioma (MPM) is increasing in incidence due to the long latency period from exposure to asbestos to development of the disease. MPM can be challenging […]

Comments Off on Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial)

Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy

Lung Cancer 2018 April [Epub 2018 February 3] [Link] Tsim S, Humphreys CA, Cowell GW, Stobo DB, Noble C, Woodward R, Kelly CA, Alexander L, Foster JE, Dick C2, Blyth K Abstract INTRODUCTION: Pleural Malignancy (PM) is often occult on subjective radiological assessment. We sought to define a novel, semi-objective Magnetic Resonance Imaging (MRI) biomarker […]

Comments Off on Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy

Podoplanin – an emerging cancer biomarker and therapeutic target

Cancer Science 2018 March 25 [Epub ahead of print] [Link] Krishnan H et. al. Abstract Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts (CAFs), and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition (EMT), migration, invasion, metastasis, […]

Comments Off on Podoplanin – an emerging cancer biomarker and therapeutic target

Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma

Journal of Cellular and Molecular Medicine 2018 March 24 [Epub ahead of print] [Link] Hsu PC, et. al. Abstract Although tumour PD-L1 (CD274) expression had been used as a predictive biomarker in checkpoint immunotherapy targeting the PD1/PD-L1 axis in various cancers, the regulation of PD-L1 (CD274) expression is unclear. Yes-associated protein (YAP), an important oncogenic […]

Comments Off on Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma

State of the Art: Advances in Malignant Pleural Mesothelioma in 2017

Journal of Thoracic Oncology 2018 March 7 [Epub ahead of print] [Link] McCambridge AJ et. al. Abstract Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. While recent epidemiological data […]

Comments Off on State of the Art: Advances in Malignant Pleural Mesothelioma in 2017

Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma

International Journal of Molecular Sciences 2018 February [Link] Martínez-Rivera V, Negrete-García MC, Ávila-Moreno F, Ortiz-Quintero B Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates in the pleura, is diagnosed in advanced stages and has a poor prognosis. Accurate diagnosis of MPM is often difficult and complex, and the gold standard […]

Comments Off on Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma

Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy

European Journal of Cancer 2018 February [Epub ahead of print] [Link] Star P, Goodwin A, Kapoor R, Conway RM, Long GV, Scolyer RA, Guitera P Abstract The germline BAP1 (BRCA1-associated protein-1) mutation and associated cancer pre-disposition syndrome was first described in 2011. Since then, physicians have considered this diagnosis for patients with a characteristic personal […]

Comments Off on Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy

Inflammatory Alteration of Human T Cells Exposed Continuously to Asbestos

International Journal of Molecular Sciences 2018 February [Link] Kumagai-Takei N, Yamamoto S, Lee S, Maeda M, Masuzzaki H, Sada N, Yu M8, Yoshitome K, Nishimura Y, Otsuki T Abstract Asbestos is a known carcinogen and exposure can lead to lung cancer and malignant mesothelioma. To examine the effects of asbestos fibers on human immune cells, […]

Comments Off on Inflammatory Alteration of Human T Cells Exposed Continuously to Asbestos

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma

Oncogenesis 2018 January [Link] Sato H et.al. Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with an unfavorable prognosis. The standard therapeutic approaches are limited to surgery, chemotherapy, and radiotherapy. Because the consequent clinical outcome is often unsatisfactory, a different approach in MPM treatment is required. S100A11, a Ca2+-binding small protein with two EF-hands, […]

Comments Off on Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma